Clinical trial
High-dose ICE With Amifostine
NCT00003657 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00003657 |
|---|---|
| Title | High-dose ICE With Amifostine |
| Official title | High Dose Ifosfamide, Carboplatin and Etoposide With Amifostine Chemoprotection |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Bladder Cancer, Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor and 2 more |
| Intervention type | Biological, Drug, Procedure |
| Interventions | filgrastim, Amifostine, Carboplatin, Etoposide, Ifosfamide, peripheral blood stem cell transplantation |
| Enrollment | 24 |
| Start date | Jul 1, 1998 |
| Primary completion | Nov 1, 2000 |
| Completion | Jun 1, 2002 |
| First posted | Mar 31, 2004 |
| Last update posted | Jan 20, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: